The clinical-stage company is focused on developing taladegib, a small-molecule inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). Taladegib has the potential to halt and even reverse IPF by targeting the underlying cause of the disease. Additionally, the company has developed ENV-101, a small-molecule inhibitor that activates during embryonic development and aids in the treatment of wound healing in adults. These inhibitors provide solutions for the treatment of cancers such as basal cell carcinoma and acute myelogenous leukemia, as well as pulmonary diseases like lung fibrosis. The company's mission is to enable healthcare professionals to provide precision treatments for terminal conditions, helping patients feel better and live longer.